Since the early 1970s, multiple drug resistance has been known to exist in cancer cells and is thought to be attributable to a membrane-bound, energy-dependent pump protein (P-glycoprotein [P-gp]) capable of extruding various related and unrelated chemotherapeutic drugs. The development of refractory disease in haematological malignancies is frequently associated with the expression of one or several multidrug resistance (MDR) genes. MDR1, multidrug resistanceassociated protein (MRP) and lung-resistance protein (LRP) have been identified as important adverse prognostic factors.
Introduction
The development of new cytotoxic drugs and treatment strategies has resulted in improved response rates for patients with haematological malignancies. However, many patients fail to respond or subsequently relapse with refractory, drug resistant disease. Tumour cells isolated from these patients often display a multidrug resistant (MDR) phenotype so that the cells are resistant to a wide range of anticancer drugs, especially natural product agents (e.g., anthracyclines, epipodophyllotoxins, taxanes and vinca alkaloids). These drugs have a few structural and functional similarities except that they are large, hydrophobic molecules and may enter the cell by passive diffusion across the cell membrane lipid bilayer. However, alkylating agents, cisplatin and antimetabolites do not share these characteristics.
The treatment in malignant haematological diseases results in an initial response in the majority of the patients. However, the remission may be of short dura-tion and it is frequently followed by a relapse of resistant tumour cells associated with clinically refractory disease. Goldie & Coldman (1983) have formulated that tumour cells may be resistant to chemotherapy prior to treatment due to spontaneous mutations. These cells expand by selection during treatment and overgrow the sensitive cells (Goldie & Coldman, 1983) . In addition to intrinsically resistant cells, MDR can develop during the treatment. Recently, the existence of so-called pleiotropic drug resistance (multidrug resistance) has been identified (Goldstein et al., 1989; Borst, 1991) . In this review we will describe the genes of MDR and approaches to reverse MDR in haematological malignancies.
Drug resistance associated with MDR1 expression
There are two different genes coding for P-glycoprotein (P-gp) in humans: MDR1 and MDR3, both located (Sonneveld & List, 2001) . Despite their homology, only MDR1-encoded P-gp is a drug efflux protein related to MDR. P-gp belongs to the superfamily of ATP-binding cassette (ABC) transporters, a family of ATP-dependent transport proteins (Dean et al., 2005) . The 170 kDa P-gp ( Fig. 1 ) consists of two structurally homologous halves, each with six trans-membrane domains, one ATP-binding site and the highly conserved 'Walker A' and 'Walker B' motifs (Hrycyna et al., 1996) . These two halves are probably derived from internal gene duplication (Chen et al., 1986) . Several studies have suggested that phosphorylation of P-gp might be essential for drug transport (Germann, 1996) . However, two different investigators have demonstrated that mutations of the major phosphorylation sites with P-gp do not affect its transport function Goodfellow et al., 1996) . The glycosylated sites of P-gp at the cellular outside are probably involved in routing and stability of the protein (Schinkel et al., 1993) , but they also serve as antigens for monoclonal antibodies. P-gp has a wide variety of substrates (Tab. 1). All of these are large hydrophobic and amphipathic molecules that do not necessarily have a structural dissimilarity. These molecules are capable of intercalation into the membrane in order to enter subsequently the cytosol by passive diffusion. It is no longer believed that P-gp is a 'classical' pump, which binds substrates from the cytoplasm and then transports these over the membrane. Hydrophobic compounds, that are substrates for P-gp do not pass the membrane into the cytosol of cells that express P-gp (Homolya et al., 1993) . It is generally assumed that an interaction of these substrates with P-gp already occurs in the cell membrane (Raviv et al., 1990) . This mechanism of transport is also postulated for a prokaryotic homologue of P-gp with similar broad substrate specificity in Lactococcus lactis, suggesting that a general function of P-gp is to protect cells against toxic substances (Bolhuis et al., 1996) . Although the exact mechanism of how this protein removes hydrophobic drugs from the cell is still not resolved, P-gp may function as a 'flippase' within the plasma membrane (Higgins & Gottesman, 1992) . It may translocate drugs actively (ATP-dependent) from the cytosolic inner lipid leaflet of the plasma membrane to the outer lipid leaflet. Subsequently, these drugs may be extricated from the plasma membrane by diffusion.
Expression of MDR1 in haematological malignancies
MDR1 is expressed in several solid and haematological malignancies (Arceci, 1993; Gottesman et al., 2002) . Tumours that are derived from tissues that normally stain P-gp positive may more frequently express the MDR1 gene (Goldstein et al., 1989; Nooter & Herweijer, 1991) . Tumours derived from the haematological compartment that frequently express P-gp includes acute myeloid leukaemia (AML), non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukaemia (ALL) (Pileri et al., 1991; Niehans et al., 1992) . High P-gp expression is frequently observed in patients who were previously treated with natural product cytostatic drugs (Goldstein et al., 1989) . This observation suggests that a selection process occurring during repeated exposure to these drugs can induce P-gp expression. In addition, anticancer agents may activate P-gp transcription (Kohno et al., 1989) . AML is a clonal disease that finds its origin in the transformation of the uncommitted stem cell. This may explain why P-gp is frequently present in blast cells at diagnosis of de novo AML. P-gp expression varies from 19 to 75% of untreated AML cases (Sato et al., 1990; Marie et al., 1991; Musto et al., 1991; Pirker, et al., 1991; Zhou et al., 1992; Te Boekhorst et al., 1995; ) and highrisk myelodysplasia (List et al., 1991) . The quantitative difference between these studies may result from the variety of analytical assays that were used for P-gp analysis. Some studies have also investigated the level of MDR1 expression in relapsed AML. Generally, patients with refractory and/or relapsed AML more frequently express MDR1 than de novo patients (Musto et al., 1991; Zhou et al., 1992; Leith et al., 1999) . A significantly lower probability to achieve a complete remission was observed in patients with MDR1 expression as determined by either RNA assays (Sato et al., 1990; Marie et al., 1991; Pirker et al. 1991 ), or Pgp staining (Guerci et al., 1995; Van Den Heuvel-Eibrink et al., 1997) . In contrast, no such correlation was found in two studies using the same assays (Paietta et al., 1994) . The lack of agreement between some studies underlines the need for standardizing the assays that are used for MDR1 analysis in AML specimens. Even with highly specific assays it is uncertain if low numbers of MDR1-expressing cells contribute to a poor outcome of treatment. In an attempt to evaluate the value of different numbers of MDR1-positive blast cells, Te Boekhorst et al. (1995) showed that even small numbers of these cells (1 ± 5%) represent an increased risk of refractory disease. These data suggest that small numbers of MDR1-positive cells are relevant for the response to treatment in de novo AML. Therefore, the assays, which are capable of detecting MDR1 expression in such small cell fractions, should be developed. In ALL, P-gp is observed in 38% of cases. In a multivariate analysis it was shown to be an independent, poor prognostic factor for response and survival in both children and adults (Goasguen et al., 1993) .
Other mechanisms of cellular resistance
Typical MDR has now been recognized as an important cause of in vitro resistance to many antileukaemic drugs, such as anthracyclines, epipodophyllotoxins and amsacrine. However, in spite of the fact that MDR1 confers clinical resistance in AML, other mechanisms of resistance seem to be involved as well ( Fig. 2 ) (Sonnveld, 2000) .
Multidrug resistance-associated protein (MRP), displaying large isoform diversity, confers resistance of tumour cells to several chemotherapeutic drugs (Tab. 1). MRP is also a member of the ABC superfamily and is capable of efflux and intracellular sequestration, in conjunction with glutathione (GSH) conjugation or co-transport (Filipits et al., 1998; Legrand et al., 1999) . The substrate specificity of MRP (Tab. 1) is similar but more limited than that of P-gp; and their normal physiologic role may be detoxification of intracellular oxidants. It has been suggested that the location of MRP genes on chromosome 16 might be a reason for the favourable prognosis for patients with AML (Chauncey et al., 2001) . Lung-resistance protein (LRP) was initially identified in a lung cancer cell line during in vitro selection for drug resistance (List et al., 1996; Filipits et al., 1998) . It has significant homology with rodent vault proteins, which are likely involved in nuclearcytoplasmic transport. Overexpression of LRP in transfection experiments is not sufficient to confer resistance, suggesting that other cofactors or post-translation assembly is necessary for biologic function (Dalton & Scheper, 1999) . On the other hand, LRP expression was increased in patients with AML at relapse following response to an induction therapy that included cyclosporin to overcome P-gp resistance (List et al., 1996) . This suggests that modulating P-gp-mediated resistance may result in selection or up-regulation of LRP as a secondary resistance mechanism after P-gp reversal.
In addition to proteins involved in active efflux of cytostatics from the cancer cells, drug resistance can occur at many levels, including drug inactivation, alteration of drug target, processing of druginduced damage, and evasion of apoptosis (Longley & Johnston, 2005) . For example, topoisomerase II is the cellular target of anthracyclines and epipodophyllotoxins, and decreased levels of topoisomerase IIα correlates with decreased sensitivity of tumours to these agents (Gieseler et al., 1996; Towatari et al., 1998) . The in vitro selection of resistant mutants in the presence of P-gp-reversing agents can lead to resistance mediated in part by lower protein levels and functional activity of topoisomerase II (Abbaszadegan et al., 1996; Chauncey, 2001) . Similarly, overexpression of Bcl-2 and other apoptosis pathway regulatory genes, such as Bcl-xL, have been associated with drug resistance in leukaemia cell lines (Nuessler et al., 1999) . Recently a novel transporter has been identified, which is called breast cancer resistance protein (BCRP), ABCG2 or mitoxantrone resistance protein (Staud & Pavek, 2005) . BCRP, confering resistance to chemotherapeutic agents, such as mitoxantrone, doxorubicin and daunorubicin, is expressed in low but variable levels in blast cells from both AML (Ross et al., 2000) and ALL patients (Plasschaetr et al., 2004) , however, further studies are warranted to investigate its effect on clinical outcome.
Multidrug resistance in human leukaemia
Drug resistance in ALL ALL, the most frequent childhood cancer, is currently treated by up front intravenous combination chemotherapy followed by consolidation therapy and by oral maintenance chemotherapy. Modern treatment regimens are most likely to contain, among other drugs, glucocorticoids, vinca alkaloids, anthracyclines, l-asparginase, and methotrexate. Current treatment results in childhood ALL have developed favourably and yield cure rates of about 80% and, furthermore, seem to be continuously improving (Pui et al., 2001) . The in vitro drug resistance in this disease has extensively been studied especially in the Netherlands and in Japan. Major findings of these investigators have been that the in vitro drug resistance in this disease is correlated to long-term clinical outcome (Hongo et al., 1997) and that the cellular drug resistance to an extent mirrors other known prognostic parameters, such as cytogenetic abnormalities (Hongo et al., 2002) and immunophenotype (Pieters et al., 1998) . A large number of specific drug resistance molecules and mechanisms have been investigated in ALL. These include P-gp and non-Pgp drug efflux mechanisms (Den Boer et al., 1999; Tafuri et al., 2002) , mechanisms related to the cellular apoptotic machinery (Wuchter et al., 2000) , mechanisms of resistance towards methotrexate -the single most important chemotherapeutic drug in this disease (Gorlick et al., 1997; Rots et al., 2000) , as well as other mechanisms (Den Boer et al., 1999) . With regard to childhood ALL, the prognostic value of ABC transporter expression in treatment failure has been considered controversial (Olson et al., 2005) . However, a recent review summarizing results of several clinical studies showed that P-gp expression and/or activity has been associated with unfavourable outcome in paediatric ALL patients, whereas MRP1 and BCRP do not seem to play a major role (Swerts et al., 2006) . LRP might contribute to drug resistance in B-lineage ALL, but larger studies are needed to confirm these results (Swerts et al., 2006) . In contrast to what has been done in AML and chronic myeloid leukaemia (CML), clinical trials evaluating reversibility of multiple drug resistance in ALL have not been carried out so far (see below).
Drug resistance in AML
The only known potentially curative treatment of AML is intravenous high-dose combination chemotherapy. The chemotherapeutic regimens for remission induction have been relatively uniform with daunorubicin in combination with cytosine arabinoside (Ara-C) for more than 7 days being considered the standard regimen. Although alternatives to this combination have been published (Wiernik et al., 1992) , none have conclusively been shown to be superior in terms of short-or longterm patient survival (Löwenberg et al., 1999) . Post remission chemotherapy improves likelihood of maintaining complete response in an Ara-C-dose dependent manner (Bloomfield et al., 1998) . As in the case of ALL, several lines of evidence indicate that the particular prognosis of certain (cyto)genetically defined subgroups of AML have their particular prognosis due to the inherent cellular drug resistance of the leukaemic cells, e.g. decreased Ara-C resistance is found in AML of Down's syndrome patients (Zwaan et al., 2002a) and in AML-cells harbouring the pericentric chromosome 16 inversion (Nøorgaard et al., 2004) , and increased Ara-C resistance is found in cells harbouring chromosome 5/7 abnormalities (Zwaan et al., 2002b) . Cellular enzymes important to resistance towards Ara-C are listed in Table 2 .
Mechanisms that may be involved in drug resistance in AML include the mechanism related to Pgp/MDR1 and a large number of non-MDR1 mechanisms of drug resistance (Tab. 2). Among the mechanisms that have been investigated in clinical trials are those caused by overexpression of P-gp/MDR1 (Legrand et al., 1999; Leith et al., 1999; Nøorgaard et al., 2004) , MRP (Legrand et al., 1999; Leith et al., 1999; Michieli et al., 1999) , LRP (Leith et al., 1999; Michieli et al., 1999) and apoptosis related proteins (Del Poeta et al., 2003) . In one study it was found that MDR1 expression prior to treatment has a negative impact not only on complete response rate, but also on remission duration and on survival (Pirker et al., 1991) . More recently, Leith et al. (1997; demonstrated that P-gp expression and function in AML patients is correlated with a reduced complete remission rate and an increased rate of resistant disease. Although the effect on response and survival was not as great as initially thought, the correlation between P-gp expression and prognosis was clearly demonstrated (Leith et al., 1999) . These data confirmed the earlier reports that MDR1 expression is an independent prognostic vari- , 1997) . So far, the largest trial in untreated patients found no correlation between MRP1 and LRP expression and prognosis (Leith et al., 1999) . In respect of apoptosis related proteins, correlation with outcome in clinical samples was initially considered inconsistent (Baker et al., 1997) , however, the independent prognostic value of bax/bcl-2 ratio in AML was confirmed in recent multivariate analysis (Del Poeta et al., 2003) . The higher bax/bcl-2 ratio was significantly associated both with a higher complete response rate and a longer overall survival (Del Poeta et al., 2003) .
Drug resistance in CLL
Although complete remission can be obtained in chronic lymphoblastic leukaemia (CLL) with currently used regimens, the goal of chemotherapy in this leukaemia is management rather than cure. By a tradition established through four decades, this leukaemia, when symptomatic and in the later stages of the disease, is treated by chlorambucil alone or in combination with glucocorticoids. Treatment in earlier stages of the disease is not mandatory (Dighiero et al., 1998) . Treatment with newer drugs including cladribine (2-Cda) and fludarabine does not significantly change the overall survival but produces significantly higher remission rates than the about 10% that can be achieved with chlorambucil alone or in combination with a glucocorticoid (Robak et al., 2000) . Cellular drug resistance in CLL has been studied by Bosanquet et al. (2002) who found a predictive value of the differential staining cytotoxicity (DiSC) assay (with fludarabine in vitro) in patients receiving fludarabine therapy, and no convincing evidence for involvement of MDR1 but for Bax rather than Bcl-2 in CLL drug resistance. Other groups have investigated the possible role of MDR1 and other mechanisms in MDR of CLL-cells and divergent results have been presented. Webb et al. (1998) in a study including NHL as well as CLL demonstrated increased expression of MDR1 and MRP in leukaemia-and lymphoma-cells of patients that had been exposed to high doses of P-gp transportable drugs. Quite in contrast, Consoli et al. (2002) in a very recent work found no corre-lation between P-gp, MRP-, and LRP-expression and the amount of previous treatment but, rather, a correlation between Bcl-2 and disease stage. In conclusion, the mechanisms of cellular MDR in CLL have been investigated to some extent. A consensus on which mechanisms play a role in this leukaemia has not been reached. Further studies are certainly warranted. Introduction of newer, more potent drugs with new modes of action emphasizes the need for investigations of cellular drug resistance in this disease (Bosanquet et al., 1999) .
Drug resistance in CML
Until 1990s, the chemotherapy of choice for chronic phase CML was orally administered chemotherapy with either hydroxyurea or busulphan (Hehlmann et al., 1993) . At that time, interferon was introduced and was found to be better than known cytotoxic chemotherapy in CML (Hehlmann et al., 1994) . A relatively recent trial conducted during the mid-1990s showed that when CML patients are cytoreduced with hydroxyurea, subsequent treatment with interferon in combination with low-dose of Ara-C yields more major cytogenetic responses and longer survival than treatment with interferon alone (Guilhot et al., 1997) .
For decades, bone marrow transplantation has been performed in younger CML patients for whom it is possible to find a human leukocyte antigen matched family member or a matched unrelated donor. Related to the bone marrow transplantation procedure there are significant risks of morbidity and mortality, but the procedure has until now been considered the only possible curative treatment in CML. When CML progresses to the accelerated and blastic phase, the available treatments including bone marrow transplantation become less effective. Treatment of blast phase CML is commonly done by intravenous administering of remission induction chemotherapy as for AML or ALL, depending on the lineage of the blast crisis. Very recently, the results of a randomised trial designed to evaluate the possible value of cyclosporin A as a drug resistance modifier in combination with high-dose Ara-C and daunorubicin in blast phase CML was published (List et al., 2002) . In brief, this study showed no benefit of addition of cyclosporin A to a standard chemotherapeutic regimen.
A major advance in the treatment of CML has the advent of imatinib which has shown a striking activity in the chronic phase, in the accelerated phase, but less so in the blast phase (Nøorgaard et al., 2004) . The whole field of drug resistance in human leukaemia and certainly in CML will, beyond any doubt, change dramatically within the next years as a consequence of the emergence of imatinib. This drug will be the first of a new series of small organic compounds designed to inhibit specific molecular sites in the cascades of cellular activation pathways. Resistance mechanisms to imatinib have to some extent been explored and include known mechanisms of drug resistance including that of P-gp (Mahon et al., 2003) as well as other mechanisms including BCR-ABL gene amplification and gene point mutations (Hofmann et al., 2002) . The limited number of clinical data show that MDR1 expression would play an important role in imatinib resistance when the disease is not fully controlled (Galimberti et al., 2005) .
Drug resistance in lymphoma
NHL is a chemotherapy sensitive tumour, but not curable in the majority of cases with currently available chemotherapy because of drug resistance. MDR is a mechanism by which cancer cells acquire resistance to a variety of structurally diverse anticancer drugs simultaneously. The expressions of MDR1 in patients with NHL were significantly higher in patients who did not respond to subsequent chemotherapy than those who did. Tumours with high grade malignancy had higher expression of MDR and topoisomerase II than those with intermediated grade malignancy (Zubercová & Babušíková, 1998) . These results suggest that MDR caused by overexpression of MDR1 and MRP plays an important role in clinical drugs resistance and that therapeutic strategy to overcome these mechanisms could improve the treatment outcome in NHL (Zubercová & Babušíková, 1998) . The poor prognosis for patients with NHL treated with chemotherapy may be explained by P-gp expression of the NHL cells (Pituch-Noworolska et al., 1995) and it is known that the expression of P-gp in NHL patients is based on blasts phenotype. In lymphoma with B cell phenotype of blast cells, the percentage of P-gp positive samples was 41%, in non-lymphoblastic leukaemia 35% and T-cell phenotype 75%. The P-gp assay selected the group of patients with higher risk of drug resistance for modified therapy (Kaczorowski et al., 1995) .
The relevance of P-gp-mediated MDR in patients with multiple myeloma (MM) and malignant lymphoma (ML) was studied in many reports. They described doxorubicin in the human tumour cloning assay and P-gp expression by immunohistochemistry (Kaczorowski et al., 1995) . Additionally, in vitro resistance could often be reversed by addition of a chemosensitizer, such us verapamil, quinine or cyclosporin. P-gp expression is only observed in tumours biopsies in 1-2% of untreated patients with MM or ML. In patients with MM or ML relapsing from treatment, 40-80% of specimens are positive for P-gp (Sonneveld, 2000) . In ML, 72% refractory patients achieved remissions on dexverapamil/verapamil. Dexverapamil, an inhibitor of P-gp, was well tolerated in NHL and Hodgkin's lymphomas (HL) refractory to chemotherapy. As summarized by Yuen & Sikic (1994) , it is unclear whether MDR expression has a significant impact on the response to therapy in lymphomas. However, recent studies suggest that P-gp-positive patients may have a poor prognosis compared to negative patients. It seems that MDR1 plays a major role in clinical resistance of lymphomas, but also other non-MDR mechanisms are possibly present in such patients (Zubercová & Babušíková, 1998) .
Assay for drug resistance
Over the years, a number of methods have been developed to measure the cellular expression or function of P-gp/MDR1. For human leukaemia, these include immunocytochemical and immunohistochemical methods, flow cytometry, measurement of P-gp function by drugor dye-efflux methods, and methods that allow quantification of MDR1 mRNA, such as RT-PCR (Table 3 ) (Nøorgaard et al., 2000) . Several assay methods of MDR1 expression are available for evaluation of clinical samples; however, they do not necessarily produce comparable results. Generally, bulk methods such as RT-PCR or Northern blot are not suitable for quantitative differences of MDR1 expression in subpopulations of cells with certain morphology, and contaminating Tcells may influence the results. With these assays, it is not possible to correlate MDR1 expression with maturation and/or differentiation markers. Therefore, most investigators prefer to determine MDR1 expression at the protein level (Sonneveld, 2000) .
Immunocytochemical/immunohistochemical methods have the inherent advantages of providing information on cytological/histological details, in addition to giving semi-quantitative information on P-gp expression. On the other hand, because some of the available antibodies cross-react with non-P-gp epitopes, it is strongly recommended that at least 2 antibodies are used, one recognizing an extracellular and one an intracellular epitope of P-gp. Because of inter-antibody as well as intra-antibody variability, it is essential to standardize preparations and regularly carry out thorough control experiments with well-established control cell lines (Nøorgaard & Hokland, 2000) . In leukaemic blast cells, P-gp expression is also frequently associated with the expression of the CD34 or CD7 antigens (Campos et al., 1992) . More recently, co-expression of P-gp and CD34 was demonstrated in AML blast cells (Te Boekhorst et al., 1993) . In the study by Leith et al. (1995) discordant expression of MDR1 was observed in CD34+ cells, i.e. P-gp staining and the Rhodamin fluorescent dye retention assay identified AML cases with different properties. This study points to the possibility that MDR1 expression may vary and/or have multiple functional properties in CD34+ AML cells. Other data suggest that the expression of P-gp/MDR1 in immature stem cells is conserved during leukaemic transformation (Campos et al., 1992) .
In addition to Rhodamin 123, the P-gp-mediated efflux of cytostatic agents such as daunorubicin, doxorubicin or vincristine can be determined in cell suspensions. Using such a functional assay, the effect of P-gp inhibition by a drug-resistance modulating agent can also be evaluated (Ludescher et al., 1992) . Together, these assays may be used to analyse the MDR profile of AML cells obtained from individual patients. Only a few studies have attempted to correlate the expression of MDR1 with in vitro drug sensitivity (Marie et al., 1991) . Beyond the considerable technical difficulties of these clonogenic assays, interpretation of the results is hampered by the fact that other mechanisms of drug resistance may also be involved.
In pre-treated NHL, the reported incidence of P-gp staining varied from 2 to 49% in untreated patients and 64% in pre-treated patients, while with mRNA analysis these figures were 22±50% and 30±60%, respectively (Sonneveld, 2000) .
For flow cytometrical detection of P-gp using monoclonal antibodies, it is recommended to use antibodies that recognize extracellular epitopes, because their use in flow cytometry allows for correlation with other cell-surface antigens by multiparameter flow cytometry and for flow cytometrical measurement of drug/dye efflux by the intact cells. To minimize variation of the flow cytometrical method, rigorous control experiments should be carried out regularly using well-characterized control cell lines. All antibody controls should be isotype matched. When using methods for measurement of drug or dye efflux, it is recommended that they are used in parallel with measurements of P-gp, by flow cytometry to distinguish between P-gp and non-P-gp-mediated drug efflux (Nøorgaard & Hokland, 2000) .
LRP can be assessed with flow cytometry, immunocytochemistry and RT-PCR. Due to cytoplasmic localization, permeabilizing agents must be used with conventional flow cytometric techniques. Furthermore, post-translation regulation can make immunologic detection inconsistent. These techniques have been compared on identical clinical samples and cell lines and the relative advantages, disadvantages, and highlights of each have been described (Legrand et al., 1998; Chauncey, 2001) .
Methyl-thiazol-tetrazolium (MTT) assay is a method of elucidating cytotoxicity of a drug (Pieters et al., 1990) . This short-term cell culture assay is based on the principle that cells surviving the drug exposure are capable of reducing 3-[4,5-dimethylthiazol-2,5-diphenyl] tetrazolium bromide (MTT) to a dark-coloured formazan. The amount of formazan produced can be determined spectrophotometrically (Pieters et al., 1990) . The methyl-thiazol-tetrazolium assay gives fast and reproducible results, however, it does not provide any information about molecular mechanism of drug resistance. In addition, methyl-thiazol-tetrazolium as the in vitro test does not completely reflect the in vivo situation.
Inhibition of ATP-dependent transporters
The interest in P-gp mediated drug resistance was markedly enhanced by the demonstration that several non-cytotoxic agents, such as verapamil (Tsuruo et al., 1981) and cyclosporin (Slater et al., 1986) , inhibit the P-gp-mediated MDR because they compete with other substrates for the binding sites of P-gp. Therefore, much effort has been devoted to the development of inhibitors of ABC transporters. Firstgeneration compounds included MDR1 inhibitors, such as verapamil and cyclosporin, were combined with a range of chemotherapy regimes for many cancers, including AML (Gottesman et al., 2002) . Since the results were not convincing, subsequent clinical trial were carried out with second-generation inhibitors, such as valspodar and biricodar. The results of these trials were negative because of pharmacokinetic interaction and possible presence of other transporters that were not targeted by the inhibitor (Dean et al., 2005) . In addition to low efficiency, strong adverse effects, cardiovascular activity of verapamil or nephrotoxicity of cyclosporin, are great disadvantage of P-gp inhibitors of first-generation. Therefore design of new inhibitors of P-gp with less adverse effects and higher efficiency is of great interest. The third-generation of P-gp inhibitors such as tariquidar and zosuquidar have high potency and specificity, and are being tested in phase III clinical trials in conjunction with chemotherapy to determine whether P-gp inhibition can restore, enhance or prolong drug sensitivity (Longley et al., 2005) . In addition to the P-gp inhibitors of third-generation, derivatives of verapamil with reduced cardiovascular activity are very promising (Teodori et al., 2005; Biscardi et al., 2006) in treatment of AML patients that achieved complete remission or presented a resistant disease. Finally, an inhibition of drug efflux might be most beneficial when combined with anticancer drug that specifically targets the stem cells, such as imatinib, which targets the leukaemia stem cells carrying the BCR-ABL fusion protein (Dean et al., 2005) .
Conclusions
Of the better-characterized markers of drug resistance in haematological malignancies, phenotypic and functional P-gp expression predicts outcome more consistently than LRP and MRP, although the prognostic utility of these and other resistance markers may change with large studies and more consistent methodology.
Despite preclinical experiments showing that some resistant phenotypes can be overcome with P-gp/MDR1 reversing agents, the cellular "resistance profile" likely represents a complex interaction of multiple cellular alterations. As such, overcoming clinical resistance in leukaemia therapy may require not only targeted resistance modifiers, but also a more complete biological and clinical understanding of the leukaemic process.
Development and refinement of molecular methods for MDR genes detection and measurement may be a major advantage, but use of these methods in the clinical setting may be limited by the inherent inability of these methods to distinguish between neoplastic cells and normal cells. In a more restricted setting, e.g. using cell lines, the molecular methods for MDR genes detection certainly have their place and have advantages over all other currently available methods. Immunological methods have their disadvantages, which include low sensitivity in detecting the presence of Pgp. By use of these methods, however, it is possible to measure P-gp expression in different subsets of cells, allowing for distinction between P-gp expression in neoplastic and normal cells of a given specimen. Based on the current literature on flow cytometry of P-gp and drug accumulation/efflux, it is strongly recommended to use the quantitative methods. In addition to classical methods, DNA microarray and proteomic technology have opened up new opportunities to detect molecules responsible for drug resistance. Improved detection of drug resistance together with new-targeted treatment strategies will permit selection of the best treatment for individual leukaemic patients.
